Amylyx Q3 net loss widens 32% year over year to $45.49 million

Bitget2026/11/05 12:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Amylyx Pharmaceuticals’ third-quarter 2026 net loss widened 32% year over year to $45.49 million.
Cash, cash equivalents and marketable securities reached $768.13 million at September 30, including approximately $544.6 million from August’s public offering.
Avexitide’s Phase 3 LUCIDITY trial met its primary endpoint, reducing the composite rate of Level 2 and Level 3 hypoglycemic events 55% versus placebo.
An avexitide FDA application remains planned by year-end 2026, with a potential launch in 2027 if approved.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611050700BIZWIRE_USPR_____20261105_BW812435) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Amylyx Q3 net loss widens 32% year over year to $45.49 million

You may also like

Crypto prices